Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | DHFR | P00374 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522342 | 0.81 | HTR7 (0.49) | HTR7DHFRFEN1L3MBTL1NPC1 | |
| SCHEMBL20522305 | 0.70 | HTR2B (0.52) | L3MBTL1RAB9AHTR2AKDM4E | |
| SCHEMBL20522394 | 0.70 | HTR7 (0.58) | HTR7FEN1HTR1AHTR2AHTR5A | |
| SCHEMBL941809 | 0.67 | HTR7 (1.00) | HTR7CYP2C19HTR1AHTR2AHTR5A | |
| SCHEMBL342315 | 0.67 | — | — | |
| SCHEMBL15244548 | 0.66 | NOS1 (0.39) | SMN1; SMN2 | |
| SCHEMBL13521268 | 0.66 | NOS1 (0.35) | ALDH1A1HPGD | |
| SCHEMBL27500236 | 0.66 | CYP1A2 (0.39) | HTR7DHFRL3MBTL1NPC1CYP1A2 | |
| SCHEMBL3200198 | 0.64 | NOS1 (0.41) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL943556 | 0.62 | TDO2 (0.40) | CYP11B2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | HTR7 3888/4885DHFR 397/4885FEN1 3414/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | HTR7 3798/4885DHFR 285/4885FEN1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.